Anthem Biosciences Limited (NSE: ANTHEM, BSE: 544449) is a Bengaluru, Karnataka-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹53,926 Cr, it ranks #196 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 11 in Pharmaceutical CDMO and CRO Services. At ₹933.60 (as of 16 Nov 2026), the share price is 5.6% below its 52-week high of ₹989.10 and 61.2% above its 52-week low of ₹579.15. The share price is up 34.5% over one year and up 7.1% over three months.
| Current Price | ₹933.60 |
|---|---|
| Market Cap | ₹53,926 Cr |
| NSE Symbol | ANTHEM |
| BSE Code | 544449 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 90.1 |
| Return on Equity | 19.45% |
| Return on Assets | 14.20% |
| 52-Week Range | ₹579.15 – ₹989.10 |
| 1-Year Price Change | +34.5% |
| 3-Month Price Change | +7.1% |
| Beta (1Y) | 0.41 |
| Dividend Yield | 0.21% |
| Headquarters | Bengaluru, Karnataka |
| Website | anthembio.com |
| Revenue | ₹594 Cr |
|---|---|
| Net Profit | ₹211 Cr |
| Net Margin | 35.6% |
| EPS (Basic) | ₹3.75 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Anthem Biosciences Limited reported revenue of ₹594 Cr in Q2 FY27, up 8.0% from ₹550 Cr in Q2 FY26 and up 42.0% from ₹418 Cr in Q1 FY27. It posted a net profit of ₹211 Cr for the quarter, against a net profit of ₹173 Cr in Q2 FY26 (up 21.9%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹418 Cr (Q1 FY27) to ₹611 Cr (Q4 FY26). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹594 Cr | ₹211 Cr | 35.6% |
| Q1 FY27 | ₹418 Cr | ₹120 Cr | 28.7% |
| Q4 FY26 | ₹611 Cr | ₹190 Cr | 31.1% |
| Q3 FY26 | ₹423 Cr | ₹93 Cr | 21.9% |
| Q2 FY26 | ₹550 Cr | ₹173 Cr | 31.5% |
| Q1 FY26 | ₹540 Cr | ₹136 Cr | 25.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 71.40% of Anthem Biosciences Limited's shares as of Sept 2026, against 74.69% in Sept 2025 (−3.29 percentage points). Delivery averaged 50.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.
1. Contract Research Development & Manufacturing Services (CRDMO)-This segment offers a range of contract research development and manufacturing services for molecules used for clinical trials. 2. Speciality Ingredients-This segment manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. 3. Segment Adjustment-NA 4. R & D Services-This segment engages in research and development services.
1. Contract Research Development & Manufacturing Services (CRDMO)-83.4% 2. Speciality Ingredients-16.6%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Anthem Biosciences Limited is trading at ₹933.60, with a market capitalisation of ₹53,926 Cr.
Anthem Biosciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Anthem Biosciences Limited has a P/E of 90.1 and a return on equity of 19.45%.
Anthem Biosciences Limited is listed on the NSE under the symbol ANTHEM and on the BSE under the scrip code 544449.
Anthem Biosciences Limited's share price is up 34.5% over one year and up 7.1% over three months. Its 52-week range is ₹579.15 to ₹989.10.
In Q2 FY27, Anthem Biosciences Limited reported revenue of ₹594 Cr and net profit of ₹211 Cr, with basic EPS of ₹3.75 (consolidated, parsed from the company's exchange filing).
Anthem Biosciences Limited reported revenue of ₹594 Cr in Q2 FY27, up 8.0% from ₹550 Cr in Q2 FY26 and up 42.0% from ₹418 Cr in Q1 FY27.
Promoters held 71.40% of Anthem Biosciences Limited's shares as of Sept 2026, against 74.69% in Sept 2025 (−3.29 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.